杰拉尼尔-杰拉尼拉对心力衰竭患者与保存的喷射分数的透气和微血管功能的影响:第二阶段,随机,安慰剂控制,交叉试验
Soufiane Nassiri1,2, Geert H D Voordes3, Loek van Heerebeek4
1Department of Cardiology, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
European journal of heart failure
|July 28, 2025
概括
格拉尼尔格拉尼拉 (GGA) 在心力衰竭患者中没有改善心脏功能或运动能力. 该研究没有发现主要结果的显著差异,但注意到GGA治疗减少了脏血流.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭在有限的治疗干预措施下构成了重大的健康挑战.
- 在临床前研究中,Geranylgeranylacetone (GGA) 已知可以改善心肌顺应和内皮功能,因此对HFpEF进行了研究.
- 在亚洲,GGA具有良好的安全性,是非处方药.
研究的目的:
- 评估Geranylgeranylacetone (GGA) 在患有心力衰竭和保存喷射分数 (HFpEF) 的患者的疗效和安全性.
- 评估GGA对HFpEF患者的透析功能和内皮功能的影响.
- 探索GGA对脏血液动力学,运动能力和生活质量的影响.
主要方法:
- 进行了第二阶段,双盲,随机,安慰剂控制,交叉试验 (格拉迪亚特-HFpEF).
- 患者接受了GGA或安慰剂3个月,随后是6周的洗期.
- 主要终点包括透缩功能 (E/e) 和反应性高血症指数 (RHI);次要终点包括功能,运动能力和生物标志物.
主要成果:
- 在初级结局中没有发现显著差异:E/e' (p=0.46) 和RHI (p=0.92).
- 随着GGA的使用,经身体表面积调整的有效脏血流 (ERPF) 和脏血流 (RBF) 的显著下降.
- 在GGA和安慰剂组之间没有报告安全结果的显著差异.
结论:
- 格拉尼尔格拉尼拉 (GGA) 在患有HFpEF的患者中,没有对透缩功能,内皮功能或运动能力产生有益影响.
- GGA治疗导致有效的脏血流量和脏血流量减少.
- 在这个HFpEF队列中,GGA的安全性概况与安慰剂相当.
相关概念视频
01:29Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:26Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
01:30Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25